Schell, M., Pflüger, I., Brugnara, G., Isensee, F., Neuberger, U., Foltyn-Dumitru, M., . . . Vollmuth, P. (2020). Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: Post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology, 22(11), . https://doi.org/10.1093/neuonc/noaa120
Chicago-Zitierstil (17. Ausg.)Schell, Marianne, et al. "Validation of Diffusion MRI Phenotypes for Predicting Response to Bevacizumab in Recurrent Glioblastoma: Post-hoc Analysis of the EORTC-26101 Trial." Neuro-Oncology 22, no. 11 (2020). https://doi.org/10.1093/neuonc/noaa120.
MLA-Zitierstil (9. Ausg.)Schell, Marianne, et al. "Validation of Diffusion MRI Phenotypes for Predicting Response to Bevacizumab in Recurrent Glioblastoma: Post-hoc Analysis of the EORTC-26101 Trial." Neuro-Oncology, vol. 22, no. 11, 2020, https://doi.org/10.1093/neuonc/noaa120.